Early kidney disease may not cause symptoms. Feeling well does not replace assessment when you have risk factors. Your history, a clinical evaluation, and changes over time all matter. [1]

Three pieces of the picture

  • Blood creatinine: a waste product linked to muscle metabolism that the kidneys remove. Muscle mass and diet also affect its level. [3]
  • eGFR — estimated glomerular filtration rate: a calculation used to estimate kidney filtration. It is an estimate, not a percentage of kidney function. [2]
  • uACR — urine albumin-to-creatinine ratio: checks for excess loss of albumin, a protein, in urine. It can reveal a problem even when filtration is preserved. It measures something different from blood creatinine. [1]

Who should ask about testing?

Testing is particularly relevant for people with diabetes, high blood pressure, cardiovascular disease, or a family history of kidney failure. Your risk determines which tests make sense and how often — there is no single schedule for every reader. [1]

In Brazil, the Brazilian Diabetes Society recommends checking eGFR and uACR starting at diagnosis of type 2 diabetes, with follow-up tailored to the person. [5]

What this looks like: three hypothetical examples

These are educational illustrations, not patient stories or diagnoses.

1. “My creatinine is normal, but I have diabetes.”

A useful question is: “Have we checked my estimated filtration and urine albumin too?” A blood creatinine result alone may leave part of the assessment incomplete. [5]

2. “I am very muscular, and my creatinine went up.”

Muscle mass, recent intense exercise, and creatine supplements can affect the result. That does not automatically make a rise harmless: previous results and your circumstances still need review. [3]

In selected situations, your clinician may use cystatin C, another blood marker, to help clarify the estimate. It has limitations too and is not a required test for everyone. [4]

3. “There is albumin in my urine. Does that mean chronic disease?”

One sample does not establish that diagnosis. Fever, a urinary tract infection, or intense exercise may temporarily increase uACR. Your clinician decides when to confirm the finding. [5]

Why do previous results matter?

Chronic kidney disease involves abnormalities persisting for at least three months. This is not advice to wait three months before seeking care: a recent deterioration needs earlier assessment. The pattern over time helps distinguish different situations. [2]

What do the 2026 updates add?

The European ESC 2026 guideline emphasizes checking kidney health in people with cardiovascular disease, using eGFR and uACR at cardiovascular diagnosis. That recommendation concerns this patient group; it is not a blanket instruction for everyone to order tests. [6]

The US AHA/ACC/ADA/ASN 2026 guidance also links heart, kidney, and metabolic health. For stages 2–4 of cardiovascular-kidney-metabolic syndrome, it recommends at least annual eGFR and uACR assessment, adjusted to risk. A clinician determines the appropriate stage and follow-up. [7]

KDIGO 2024 remains the current global reference, with a focused treatment update in development. New guidance informs individualized decisions; it is not a reason to change medication on your own. [9]

What to bring to your appointment

  • Current and previous lab reports, including dates.
  • A list of medications, including over-the-counter anti-inflammatory pain relievers, supplements, and creatine.
  • Information about blood pressure, diabetes, family history, and recent health changes.
  • Questions: “Does any result need confirmation?”, “What changes in my care?” and “When should we check again?”

This checklist supports a conversation, not self-directed testing. Do not stop prescribed treatment without medical advice.

Explore the details

Choose a related guide based on the questions you want to discuss at your appointment:

The MERHI ONE educational guide to creatinine, eGFR, and albuminuria explains the markers in more depth. Here, the priority is preparing for a useful discussion: understand your results in context with your healthcare professional.

Dr. Elias Tamer Merhi Júnior is licensed to practice medicine in Brazil. This English-language article is educational and does not offer medical practice in the United States. Seek individual care from a professional licensed where you are located.

Sources and further reading

Sources checked September 12, 2026. The Brazilian Diabetes Society chapter was last revised July 4, 2024, although its portal is labeled the 2026 edition. The ESC and AHA links are official summaries of the 2026 guidelines.